(firstQuint)Study of Iguratimod in Sjgren's Syndrome.

 In this study, patients with Sjogren's Syndrome are enrolled and received Iguratimod 25 mg twice a day for 24 weeks.

 The differences of ESSPRI (EULAR Sjogren's Syndrome Patient Reported Index) score, ESSPRI(EULAR Sjogren's Syndrome Patient Reported Index) score, unstimulated salivary flow rate, Schirmer's test SF-36 score and HAQ score between baseline and week 24 are evaluated to determine the efficacy of Iguratimod in patients with Sjogren's Syndrome.

.

 Study of Iguratimod in Sjgren's Syndrome@highlight

A single-center, self-control, open-label study of efficacy and safety of Iguratimod in patients with Sjogren's Syndrome